168 related articles for article (PubMed ID: 21878940)
1. Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer.
Mita AC; Papadopoulos K; de Jonge MJ; Schwartz G; Verweij J; Mita MM; Ricart A; Chu QS; Tolcher AW; Wood L; McCarthy S; Hamilton M; Iwata K; Wacker B; Witt K; Rowinsky EK
Br J Cancer; 2011 Sep; 105(7):938-44. PubMed ID: 21878940
[TBL] [Abstract][Full Text] [Related]
2. Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503).
Brahmer JR; Lee JW; Traynor AM; Hidalgo MM; Kolesar JM; Siegfried JM; Guaglianone PP; Patel JD; Keppen MD; Schiller JH
Eur J Cancer; 2014 Jan; 50(2):302-8. PubMed ID: 24246704
[TBL] [Abstract][Full Text] [Related]
3. Skin rash as useful marker of erlotinib efficacy in NSCLC and its impact on clinical practice.
Fiala O; Pesek M; Finek J; Krejci J; Ricar J; Bortlicek Z; Benesova L; Minarik M
Neoplasma; 2013; 60(1):26-32. PubMed ID: 23067213
[TBL] [Abstract][Full Text] [Related]
4. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
Papadimitrakopoulou VA; Soria JC; Jappe A; Jehl V; Klimovsky J; Johnson BE
J Thorac Oncol; 2012 Oct; 7(10):1594-601. PubMed ID: 22968184
[TBL] [Abstract][Full Text] [Related]
5. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
Reck M; van Zandwijk N; Gridelli C; Baliko Z; Rischin D; Allan S; Krzakowski M; Heigener D
J Thorac Oncol; 2010 Oct; 5(10):1616-22. PubMed ID: 20736854
[TBL] [Abstract][Full Text] [Related]
6. Dosing to rash?--The role of erlotinib metabolic ratio from patient serum in the search of predictive biomarkers for EGFR inhibitor-mediated skin rash.
Steffens M; Paul T; Hichert V; Scholl C; von Mallek D; Stelzer C; Sörgel F; Reiser B; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
Eur J Cancer; 2016 Mar; 55():131-9. PubMed ID: 26820683
[TBL] [Abstract][Full Text] [Related]
7. A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.
Gitlitz BJ; Bernstein E; Santos ES; Otterson GA; Milne G; Syto M; Burrows F; Zaknoen S
J Thorac Oncol; 2014 Apr; 9(4):577-82. PubMed ID: 24736085
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer.
Mok T; Wu YL; Au JS; Zhou C; Zhang L; Perng RP; Park K
J Thorac Oncol; 2010 Oct; 5(10):1609-15. PubMed ID: 20808255
[TBL] [Abstract][Full Text] [Related]
9. [Erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC)].
Tang CH; Liu XQ; Gao HJ; Li JJ; Guo WF; Li XY; Wang WX; Liu B; Qu LL; Wang WW
Zhonghua Zhong Liu Za Zhi; 2010 Feb; 32(2):143-7. PubMed ID: 20403247
[TBL] [Abstract][Full Text] [Related]
10. Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC).
Cohen MH; Johnson JR; Chattopadhyay S; Tang S; Justice R; Sridhara R; Pazdur R
Oncologist; 2010; 15(12):1344-51. PubMed ID: 21148614
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study.
Kubota K; Nishiwaki Y; Tamura T; Nakagawa K; Matsui K; Watanabe K; Hida T; Kawahara M; Katakami N; Takeda K; Yokoyama A; Noda K; Fukuoka M; Saijo N
J Thorac Oncol; 2008 Dec; 3(12):1439-45. PubMed ID: 19057270
[TBL] [Abstract][Full Text] [Related]
12. A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
Kobayashi T; Koizumi T; Agatsuma T; Yasuo M; Tsushima K; Kubo K; Eda S; Kuraishi H; Koyama S; Hachiya T; Ohura N
Cancer Chemother Pharmacol; 2012 May; 69(5):1241-6. PubMed ID: 22278730
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of erlotinib for Japanese patients with previously treated non-small-cell lung cancer harboring EGFR mutations: results of Lung Oncology Group in Kyushu (LOGiK0803).
Yamada K; Takayama K; Kawakami S; Saruwatari K; Morinaga R; Harada T; Aragane N; Nagata S; Kishimoto J; Nakanishi Y; Ichinose Y
Jpn J Clin Oncol; 2013 Jun; 43(6):629-35. PubMed ID: 23599349
[TBL] [Abstract][Full Text] [Related]
14. Optimal strength and timing of steroids in the management of erlotinib-related skin toxicities in a post-marketing surveillance study (POLARSTAR) of 9909 non-small-cell lung cancer patients.
Yamazaki N; Kiyohara Y; Kudoh S; Seki A; Fukuoka M
Int J Clin Oncol; 2016 Apr; 21(2):248-253. PubMed ID: 26499382
[TBL] [Abstract][Full Text] [Related]
15. Survival outcomes in patients with advanced non-small cell lung cancer treated with erlotinib: expanded access programme data from Belgium (the TRUST study).
Van Meerbeeck J; Galdermans D; Bustin F; De Vos L; Lechat I; Abraham I
Eur J Cancer Care (Engl); 2014 May; 23(3):370-9. PubMed ID: 24152297
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.
Yoshioka H; Hotta K; Kiura K; Takigawa N; Hayashi H; Harita S; Kuyama S; Segawa Y; Kamei H; Umemura S; Bessho A; Tabata M; Tanimoto M;
J Thorac Oncol; 2010 Jan; 5(1):99-104. PubMed ID: 19898258
[TBL] [Abstract][Full Text] [Related]
17. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies.
Wacker B; Nagrani T; Weinberg J; Witt K; Clark G; Cagnoni PJ
Clin Cancer Res; 2007 Jul; 13(13):3913-21. PubMed ID: 17606725
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of erlotinib in patients with advanced non‑small‑cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics.
Motoshima K; Nakamura Y; Sano K; Ikegami Y; Ikeda T; Mizoguchi K; Takemoto S; Fukuda M; Nagashima S; Iida T; Tsukamoto K; Kohno S
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1299-1304. PubMed ID: 24121455
[TBL] [Abstract][Full Text] [Related]
19. [The cost-effectiveness analysis of gefitinib or erlotinib in the treatment of advanced EGFR mutant non-small cell lung cancer patients].
Ma Y; Huang Y; Zhao H; Liu J; Chen L; Wu H; Zhou N
Zhongguo Fei Ai Za Zhi; 2013 Apr; 16(4):203-10. PubMed ID: 23601301
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer.
Akerley W; Boucher KM; Bentz JS; Arbogast K; Walters T
J Thorac Oncol; 2009 Feb; 4(2):214-9. PubMed ID: 19179899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]